Kurmasheva, Raushan T.

The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Kendsersky, N. M., Lindsay, J., Kolb, E. A., Smith, M. A., Teicher, B. A., Erickson, S. W., Earley, E. J., Mosse, Y. P., Martinez, D., Pogoriler, J., et al. (2021) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 120

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis

Murphy, B., Yin, H., Maris, J. M., Kolb, E. A., Gorlick, R., Reynolds, C. P., Kang, M. H., Keir, S. T., Kurmasheva, R. T., Dvorchik, I., et al. (2016) · Cancer Research

Animal testing and alternativesCancer Cells and Metastasis

Cited by 69

Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma

Wang, Y., Tian, X., Zhang, W., Zhang, Z., Lazcano, R., Hingorani, P., Roth, M. E., Gill, J. D., Harrison, D. J., Xu, Z., et al. (2022) · Molecular Cancer Therapeutics

Sarcoma Diagnosis and TreatmentAdvanced Proteomics Techniques and Applications

Cited by 37

Initial Testing (Stage 1) of MK‐8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program

Kang, M. H., Reynolds, C. P., Kolb, E. A., Gorlick, R., Carol, H., Lock, R., Keir, S. T., Maris, J. M., Wu, J., Lyalin, D., et al. (2016) · Pediatric Blood & Cancer

Cancer-related Molecular PathwaysCancer Mechanisms and Therapy

Cited by 36

Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium

Hingorani, P., Zhang, W., Zhang, Z., Xu, Z., Wang, W.-L., Roth, M. E., Wang, Y., Gill, J. B., Harrison, D. J., Teicher, B. A., et al. (2022) · Molecular Cancer Therapeutics

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 28

Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma

Phelps, D., Bondra, K., Seum, S., Chronowski, C., Leasure, J., Kurmasheva, R. T., Middleton, S., Wang, D., Mo, X., & Houghton, P. J. (2015) · Pediatric Blood & Cancer

Cancer-related Molecular PathwaysSarcoma Diagnosis and Treatment

Cited by 27

Initial testing of JNJ‐26854165 (Serdemetan) by the pediatric preclinical testing program

Smith, M. A., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Maris, J. M., Keir, S. T., Morton, C. L., Reynolds, C. P., Kang, M. H., et al. (2012) · Pediatric Blood & Cancer

Cancer-related Molecular PathwaysAcute Lymphoblastic Leukemia research

Cited by 26

Abstract LB-217: Preclinical evaluation of trastuzumab deruxtecan (T-DXd; DS-8201a), a HER2 antibody-drug conjugate, in pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC)

Hingorani, P., Zhang, W., Kurmasheva, R., Zhang, Z., Wang, Y., Xu, Z., Roth, M., Gill, J., Harrison, D., Erickson, S., et al. (2020) · Cancer Research

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 6